The drug Abiraterone 250 mg (Zytiga) belongs to the group of antineoplastic agents that act by reducing the level of androgens in the male body. This type of hormone as androgen is inherent in the male half of humanity, therefore this medicine was developed for them. The active substance abiraterone reduces the number of cancer cells in the prostate gland. The drug Abiraterone 250 mg (Zytiga) is prescribed for men after contacting an oncological center and confirming the diagnosis of a prostate tumor, that is, it is metastatic castration-resistant prostate cancer. The substance abiraterone acts as a kind of blocker of steroid hormones in men - androgens. It significantly reduces their production in the body, which inhibits the growth of tumor cells. Abiraterone 250 mg removes the CYP17 enzyme, which is necessary for the normal biosynthesis of androgenic hormones, which breaks the connection with testosterone production and reduces the level of the latter in the patient's blood. The tumor gradually begins to decrease in size. After taking the drug, the highest plasma concentration is visualized after two hours. The drug is metabolized mainly by the liver. It is excreted by the intestines - 88% and 5% by the kidneys.